Patents by Inventor Bernhard Janowski

Bernhard Janowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the Purification of G-CSF
    Publication number: 20210070822
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Application
    Filed: October 21, 2020
    Publication date: March 11, 2021
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Blaschke
  • Method for the purification of G-CSF
    Patent number: 10844103
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 24, 2020
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • NOVEL PRONGF MUTANTS AND USES THEREOF IN THE PRODUCTION OF BETA-NGF
    Publication number: 20200031893
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 30, 2020
    Inventors: Susan LOREY, Bernhard JANOWSKI, Heiko PULTKE, Daniela KATHMANN, Antje PARTHIER, Andreas ANTON
  • ProNGF mutants and uses thereof in the production of beta-NGF
    Patent number: 10308694
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 4, 2019
    Assignee: Wacker Chemie AG
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • Method for the Purification of G-CSF
    Publication number: 20180094036
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Application
    Filed: October 10, 2017
    Publication date: April 5, 2018
    Applicant: Sandoz AG
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • Method for the purification of G-CSF
    Patent number: 9815879
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: November 14, 2017
    Assignee: Sandoz AG
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • ProNGF mutants and uses thereof in the production of beta-NGF
    Patent number: 9617322
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: April 11, 2017
    Assignee: Wacker Chemie AG
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • NOVEL PRONGF MUTANTS AND USES THEREOF IN THE PRODUCTION OF BETA-NGF
    Publication number: 20160244496
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 25, 2016
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • NOVEL PRONGF MUTANTS AND USES THEREOF IN THE PRODUCTION OF BETA-NGF
    Publication number: 20150087020
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Application
    Filed: December 19, 2012
    Publication date: March 26, 2015
    Applicant: WACKER CHEMIE AG
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • Method for the Purification of G-Csf
    Publication number: 20080260684
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Application
    Filed: July 14, 2006
    Publication date: October 23, 2008
    Applicant: BIOCEUTICALS ARZNEIMITTEL AG
    Inventors: Arndt Dietrich, Bernhard Janowski, Jorg Schaffner, Ulrich Kurt Blaschke